These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38415009)

  • 41. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
    Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
    J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
    Zheng Z; Wang J; Wu T; He M; Wang J; Pan Y; Chen J; Hu D; Xu L; Zhang Y; Chen M; Zhou Z
    J Hepatocell Carcinoma; 2023; 10():2117-2132. PubMed ID: 38053944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy.
    Li X; Wang J; Ding X; Xu Y; Yu M; Wu H; Deng N; Li W; Chen J
    Front Pharmacol; 2022; 13():1032881. PubMed ID: 36703739
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
    Choi NR; Kim JY; Hong JH; Hur MH; Cho H; Park MK; Kim J; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    BMC Gastroenterol; 2022 Mar; 22(1):135. PubMed ID: 35337274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.
    Jun BG; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Lee SH; Kim HS; Kang SH; Kim MY; Baik SK; Lee M; Kim TS; Choi DH; Choi SH; Suk KT; Kim DJ; Cheon GJ
    PLoS One; 2018; 13(7):e0201316. PubMed ID: 30059513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.
    Lv JW; Chen YP; Huang XD; Zhou GQ; Chen L; Li WF; Tang LL; Mao YP; Guo Y; Xu RH; Ma J; Sun Y
    Cancer; 2017 Sep; 123(18):3540-3549. PubMed ID: 28493307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.
    Wang K; Jiang G; Jia Z; Zhu X; Ni C
    Medicine (Baltimore); 2018 Jun; 97(22):e10940. PubMed ID: 29851833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
    Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
    Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
    Li X; Zhong X; Chen ZH; Xing YF; Wu DH; Chen J; Ma XK; Lin Q; Wen JY; Wei L; Wang TT; Ruan DY; Lin ZX; Wu XY; Dong M
    Asian Pac J Cancer Prev; 2014; 15(22):9635-41. PubMed ID: 25520081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
    Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
    Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice.
    Lin LW; Ke K; Chen R; Yang WZ; Huang N; Wu ZZ
    Front Immunol; 2023; 14():1286771. PubMed ID: 38288113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.
    Liu J; Shen H; Huang S; Lin J; Yan Z; Qian G; Lu Z; Wan X; Zhang F; Wang K; Zhang Y; Li J
    World J Surg Oncol; 2023 Feb; 21(1):42. PubMed ID: 36765340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G; Yin L; Liu R; Cui Y
    Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
    Li C; Li ZC; Ma L; Li LQ; Zhong JH; Xiang BD; Gong WF
    Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):749-756. PubMed ID: 32552297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
    Li X; Zhong X; Chen ZH; Wang TT; Ma XK; Xing YF; Wu DH; Dong M; Chen J; Ruan DY; Lin ZX; Wen JY; Wei L; Wu XY; Lin Q
    Asian Pac J Cancer Prev; 2015; 16(18):8665-70. PubMed ID: 26745134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
    Zhang T; Zhu C; Zhang N; Zhang L; Wang S; Xun Z; Xu Y; Yang X; Lu X; Zhao H
    Int Immunopharmacol; 2024 Mar; 129():111642. PubMed ID: 38325044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of HBV DNA load on the safety and prognosis of systematic therapy in advanced hepatocellular carcinoma].
    Zheng XR; Peng JX; Song X; Liu B; Zhong C; Chen XY; Zhang BX; Peng L; Zhu KS; Xie C
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1160-1167. PubMed ID: 38583047
    [No Abstract]   [Full Text] [Related]  

  • 60. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.